GlobeNewswire 3/30/2021 Silence Therapeutics Reports Full-year 2020 Results
GlobeNewswire 3/4/2021 Silence Therapeutics to Present at the Barclays Global Healthcare Conference
GlobeNewswire 2/26/2021 Silence Therapeutics and Mallinckrodt Initiate Work on Third Target as Part of Ongoing RNAi Research...
GlobeNewswire 2/22/2021 Silence Therapeutics to Participate in March Investor Conferences
GlobeNewswire 2/18/2021 Silence Therapeutics to Present at the 2021 SVB Leerink Global Healthcare Conference
GlobeNewswire 2/17/2021 Silence Therapeutics Initiates Dosing in Phase 1 Clinical Trial of SLN360 for Cardiovascular Disease...
GlobeNewswire 2/5/2021 Silence Therapeutics plc Announces $45 Million Private Placement
GlobeNewswire 1/6/2021 Silence Therapeutics Appoints Michael H. Davidson, MD, to Board of Directors
GlobeNewswire 1/6/2021 Silence Therapeutics Appoints Craig Tooman as Chief Financial Officer  
GlobeNewswire 1/5/2021 Silence Therapeutics to Participate in January Virtual U.S. Investor Conferences
GlobeNewswire 11/16/2020 Silence Therapeutics Presents Positive Pre-Clinical Data for SLN360 for the Treatment of Elevated Li...
GlobeNewswire 11/2/2020 Oryzon Announces Appointment of Dr. Torsten Hoffmann as Global R&D Director and Retirement of Dr. Ta...
GlobeNewswire 11/2/2020 Silence Therapeutics Appoints Dr. Marie Wikström Lindholm to its Executive Leadership Team
GlobeNewswire 10/8/2020 Silence Therapeutics Announces Change to Executive Leadership Team
GlobeNewswire 10/1/2020 Silence Therapeutics to Participate in the Chardan Virtual 4th Annual Genetic Medicines Conference
GlobeNewswire 9/14/2020 Silence Therapeutics Reports Interim Results for the Six Months Ended 30 June 2020
GlobeNewswire 9/14/2020 Silence Therapeutics Appoints Mark Rothera as President and Chief Executive Officer
GlobeNewswire 9/8/2020 Silence Therapeutics Provides Research and Development Update
GlobeNewswire 9/8/2020 Silence Therapeutics Announces Instructions for Exchanging Listed Ordinary Shares into Nasdaq Listed...
GlobeNewswire 9/8/2020 Silence Therapeutics Announces U.S. SEC Declares Registration Statement Effective and NASDAQ Approve...
GlobeNewswire 7/16/2020 Silence Announces Mallinckrodt Exercise of Options for Two Additional Complement Targets
GlobeNewswire 4/14/2020 Silence Therapeutics Final results for the year ended 31 December 2019
GlobeNewswire 4/2/2020 Silence Therapeutics to Deliver Virtual Presentation at the Annual Needham Healthcare Conference and...
GlobeNewswire 3/25/2020 Silence Therapeutics Announces R&D Update
GlobeNewswire 3/25/2020 Collaboration with AstraZeneca